Nathalie Guillo

USPTO Granted Patents = 10 (Patent Applications = 1)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 31(Granted Patents)

Location History:

Toulouse, FR (2008 - 2011)
Paris, FR (2015 - 2020)

Company Filing History:

4. 1 out of 832,680

Other

patents

Years Active: 2008-2020

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10772946 - Immunogenic compositions against (2020-09-15),

2. 9856257 - Pyrazolonaphthyridinone derivatives as MetAP2 inhibitors (methionine aminopeptidase type-2) (2018-01-02),

3. 9206177 - Substituted dimeric quinazoline-2,4-diones as FGF receptor agonists (2015-12-08),

4. 9169246 - Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof (2015-10-27),

5. 9120819 - FGF-receptor agonist dimeric compounds (2015-09-01),

6. 9034898 - FGF receptor (FGFR) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof (2015-05-19),

7. 8034828 - Use of FGF inhibiting substituted 1,2,3 indolizine derivatives in the preparation of medicaments which can be used to treat diseases linked to pathological choroidal angiogenesis (2011-10-11),

8. 7803811 - 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them (2010-09-28),

9. 7553845 - Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives (2009-06-30),

10. 7442708 - 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same (2008-10-28),

Title: Nathalie Guillo: Pioneering Innovations in Immunogenic Compositions

Introduction

Nathalie Guillo is a prominent inventor based in Paris, France, renowned for her significant contributions to the field of immunology and drug discovery. With a remarkable record of 10 patents, her innovative work continues to shape therapeutic approaches in modern medicine.

Latest Patents

Nathalie's latest patents include groundbreaking inventions in immunogenic compositions. One such patent relates to a conjugate of a saccharide covalently bound to a carrier protein. This conjugate features a saccharide comprising repetitive units of 1,5 ribitol phosphate, where all ribitol residues are substituted by N-acetyl D-glucosaminyl residues at the 4-position. Importantly, these residues exist exclusively in anomeric configurations of either α or β, with the carrier protein providing at least one epitope recognized by T helper lymphocytes.

Another significant patent pertains to Pyrazolonaphthyridinone derivatives, which serve as inhibitors of type 2 methionine aminopeptidase (hMETAP2). This invention outlines the preparation and therapeutic use of these selective inhibitors, highlighting Nathalie's versatility in both immunological and pharmacological advancements.

Career Highlights

Nathalie Guillo has had a successful career, having worked with leading companies such as Sanofi and Sanofi-Aventis. Her experience in these organizations has allowed her to develop a strong background in research and development, significantly contributing to her success as an inventor.

Collaborations

Throughout her career, Nathalie has collaborated with esteemed colleagues, including Francoise Bono and Alain Badorc. These collaborations have fostered an environment of innovation, leading to the development of cutting-edge technologies and patented solutions.

Conclusion

Nathalie Guillo stands out as an influential inventor in the realm of immunogenic compositions and drug development. Her contributions, reflected in her numerous patents, illustrate her commitment to advancing scientific knowledge and therapeutic applications. With a solid foundation in both academia and industry, her work continues to inspire future innovations in healthcare.

This text is generated by artificial intelligence and may not be accurate.